August 5, 2024
On July 30, 2024, Pfizer announced that they have made the difficult decision to discontinue the investigation of CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, for ambulatory patients with Duchenne muscular dystrophy.
To read their discontinuation update, please click here.
To read last month’s results announcement for CIFFREO, please click here.
Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | [email protected]
Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)
Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!
Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.
